Because it is found to also be upregulated in ovarian carcinoma[31,32], and its deregulation has been associated with platinum-drug resistance[33,34], mTOR represents an attractive biological target for ovarian cancer therapy. This evidence concerns the gene MTOR and ovarian cancer.